Lancashire and South Cumbria
Formulary
 
back
8 Malignant disease and immunosuppression

The majority of systemic anti-cancer therapies are not listed in this formulary as they are included in either the Lancashire and South Cumbria Cancer Alliance SACT protocols or the Cancer Drugs Fund list, produced by NHSE. 
08-02 Drugs affecting the immune response

Atezolizumab Tecentriq®
Formulary
Concentrate for solution for infusion
 
From 19th July 2025, Atezolizumab will be routinely commissioned by NHS England in accordance with NICE TA1071.
Link  NICE TA1071: Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer

Red View adult BNF  View SPC online  View childrens BNF
Blinatumomab Blincyto®
Formulary

38.5 micrograms powder for concentrate and solution for infusion
Link  NICE TA1049: Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive minimal residual disease-negative B-cell precursor acute lymphoblastic leukaemia

Red View adult BNF  View SPC online  View childrens BNF
Ozanimod Zeposia®
Formulary

Capsules 230microgram, 460microgram, 920 microgram
Link  NICE TA706: Ozanimod for treating relapsing–remitting multiple sclerosis

Do Not Prescribe View adult BNF  View SPC online  View childrens BNF